| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,482 |
2,428 |
$36K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,839 |
4,795 |
$31K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,723 |
3,439 |
$20K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
7,053 |
6,503 |
$15K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,338 |
1,250 |
$14K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
31 |
31 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
748 |
427 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,588 |
1,543 |
$911.59 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
360 |
330 |
$893.47 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
149 |
60 |
$868.48 |
| 87581 |
|
44 |
44 |
$252.63 |
| 81003 |
|
842 |
792 |
$148.75 |
| 87500 |
|
32 |
17 |
$112.28 |
| 87641 |
|
14 |
14 |
$111.16 |
| 86684 |
|
32 |
32 |
$76.02 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
12 |
12 |
$36.16 |
| 0012A |
|
18 |
18 |
$32.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
51 |
50 |
$18.39 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
25 |
24 |
$5.62 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
18 |
18 |
$0.35 |
| 99072 |
|
113 |
106 |
$0.00 |
| 99051 |
|
14 |
14 |
$0.00 |
| 91301 |
|
23 |
23 |
$0.00 |